The Charles M. Vallee Biorepository for Long COVID Science
EMORY & VANDERBILT UNIVERSITY MEDICAL CENTERS
WES ELY, MD, MPH
Critical care pulmonologist, Professor of Medicine, and Co-Director of the Center for Critical Illness, Brain Dysfunction, and Survivorship, Vanderbilt University Medical Center
VINCENT MARCONI, MD
Professor of Medicine and Global Health, Division of Infectious Disease, Emory University School of Medicine
Purpose & Vision
The Charles M. Vallee Biorepository is built on a simple conviction: the sacrifices made by trial participants should generate the broadest possible scientific return. While REVERSE-LC tests baricitinib as a treatment for Long COVID, the biorepository ensures that specimens collected from 550 participants across four timepoints are preserved for a decade — available to investigators worldwide to investigate the biological and immunological mechanisms of Long COVID, identify biomarkers for diagnosis and prognosis, and accelerate the development of effective therapies.
The impact of this resource extends well beyond academia. Findings enabled by the biorepository have the potential to directly inform clinical practice — guiding how healthcare providers diagnose, manage, and treat patients living with Long COVID.
Investigators from institutions without independent sample storage funding have already approached the team to explore integrating their samples into the biorepository. The repository is envisioned as a shared resource for the global Long COVID research community.
➤ Biological mechanisms: Investigations into the immunological and biological factors underlying Long COVID pathogenesis.
➤ Biomarker discovery: Identification of markers for diagnosis, prognosis, and predicting treatment response.
➤ Collaborative research: Open access for scientists across disciplines and institutions to address the many open questions in Long COVID.
Visit the REVERSE-LC Study Site →